Cis-Jasmone

Cis-Jasmone

SCHEMBL57545

CCC=CCC1=C(C)CCC1=O

nearest known ligand 0.30

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cis-Jasmone SCHEMBL20383 1.00 TRPA1 (0.30) TRPA1
Cis-Jasmone SCHEMBL17629672 1.00 TRPA1 (0.30) TRPA1
Cis-Jasmone SCHEMBL20385 1.00 TRPA1 (0.30) TRPA1
Cis-Jasmone SCHEMBL901284 1.00 TRPA1 (0.30) TRPA1
Cis-Jasmone SCHEMBL8675317 0.91 AKR1C4 (0.34)
SCHEMBL11804819 0.82
SCHEMBL3110758 0.82
SCHEMBL20384 0.82
SCHEMBL13886351 0.79 ALDH1A1 (0.30)
SCHEMBL23849743 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12589377-B2 Encapsulated composition comprising core-shell microcapsules and process for its preparation GIVAUDAN SA (CH) 2026-03-31 US claimed
US-20260068882-A1 ARTHROPOD CONTROLLING COMPOSITION FIRMENICH & CIE (CH) 2026-03-12 US claimed
US-12559703-B2 Fragrance composition GIVAUDAN SA (CH) 2026-02-24 US claimed
CN-111051483-B Esters and ethers of 2, 4-tetramethyl cyclobutane-1, 3-diol as fragrance chemicals 巴斯夫欧洲公司 2025-01-24 CN claimed
US-12187978-B2 Use of (3-acetoxy-2,2-dimethyl-propyl) acetate in combination with (3-hydroxy-2,2-dimethyl-propyl) acetate as an aroma chemical BASF SE (DE) 2025-01-07 US claimed
WO-2024211130-A1 METHODS FOR MODIFYING MEIOTIC RECOMBINATION IN PLANTS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2024-10-10 WO claimed
US-20240206778-A1 FRAGRANCE FOR IMPROVING INVIGORATION STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2024-06-27 US claimed
US-20240197221-A1 FRAGRANCE FOR IMPROVING HAPPINESS STATE AND METHOD OF ASSESSING GIVAUDAN SA (CH) 2024-06-20 US claimed
CN-113873884-B Arthropod control composition 弗门尼舍有限公司 2024-06-14 CN claimed
US-20240173230-A1 FRAGRANCE COMPOSITION GIVAUDAN SA (CH) 2024-05-30 US claimed
US-20070071780-A1 Personal care composition comprising a perfume booster accord PROCTER & GAMBLE COMPANY, THE 2007-03-29 US claimed
US-20050136022-A1 Cyclic siloxane compositions for the release of active ingredients MOMENTIVE PERFORMANCE MATERIALS INC. 2005-06-23 US claimed
US-20050136021-A1 Active-releasing cyclic siloxanes MOMENTIVE PERFORMANCE MATERIALS INC. 2005-06-23 US claimed
US-20020102280-A1 Solvent systems for pharmaceutical agents LYOTROPIC THERAPEUTICS, INC. 2002-08-01 US claimed
US-6121234-A ORALLY COADMINISTERING TO MAMMAL PHARMACEUTICAL COMPOUND AND ESSENTIAL OIL AVMAX, INC. (US) 2000-09-19 US claimed
US-5919440-A HIGHLY VOLATILE PERFUME, IONE PERFUME, MUST, POLYMER PROCTER & GAMBLE COMPANY (US) 1999-07-06 US claimed
US-5874073-A IONONE PERFUME, MUSK, VOLATILE PERFUME PROCTER & GAMBLE (US) 1999-02-23 US claimed
US-5716928-A ADMINISTERING DRUG CONCURRENTLY WITH ESSENTIAL OIL AVMAX, INC. (US) 1998-02-10 US claimed
US-5665386-A Use of essential oils to increase bioavailability of oral pharmaceutical compounds AVMAX, INC. (US) 1997-09-09 US claimed
US-3941828-A Process for the preparation of cyclic ketones FIRMENICH SA (CH) 1976-03-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260068882-A1 ARTHROPOD CONTROLLING COMPOSITION CNOT9, MSL1, MT-CO2 TRPA1 794/4885
US-12589377-B2 Encapsulated composition comprising core-shell microcapsules and process for its preparation CUTA, EXOC1, EXOSC10 TRPA1 2091/4885
US-12559703-B2 Fragrance composition DHCR24, OPRD1, OR10J3 TRPA1 66/4885
US-20050136022-A1 Cyclic siloxane compositions for the release of active ingredients F9, RPL39, ECPAS TRPA1 469/4885
US-20050136021-A1 Active-releasing cyclic siloxanes F9, RPL39, ALDH16A1 TRPA1 489/4885
US-20240173230-A1 FRAGRANCE COMPOSITION FABP2, FABP5, FAAH2 TRPA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.